Edition:
United States

Infinity Pharmaceuticals Inc (INFI.OQ)

INFI.OQ on NASDAQ Stock Exchange Global Select Market

2.28USD
20 Oct 2017
Change (% chg)

$-0.12 (-5.00%)
Prev Close
$2.40
Open
$2.43
Day's High
$2.45
Day's Low
$2.27
Volume
513,693
Avg. Vol
370,262
52-wk High
$3.84
52-wk Low
$0.84

Chart for

About

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145,... (more)

Overall

Beta: 2.87
Market Cap(Mil.): $115.57
Shares Outstanding(Mil.): 50.69
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.38 16.52
EPS (TTM): -- -- --
ROI: -- 2.39 11.32
ROE: -- 3.35 15.18

BRIEF-Verastem makes milestone payment to Infinity Pharmaceuticals

* Verastem pays milestone payment to Infinity Pharmaceuticals

Oct 17 2017

BRIEF-Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration

* Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration evaluating ipi-549 in combination with Opdivo (nivolumab)

Sep 25 2017

BRIEF-Infinity Q2 loss per share $0.34

* Infinity provides company update and reports second quarter 2017 financial results

Aug 03 2017

BRIEF-Infinity amends PI3K-Delta,Gamma Agreement with Takeda Oncology

* Infinity amends PI3K-Delta,Gamma Agreement with Takeda Oncology

Jul 27 2017

BRIEF-Infinity reports Q1 loss per share $0.21

* Infinity provides company update and reports first quarter 2017 financial results

May 09 2017

Competitors

Earnings vs. Estimates